Although the role of A2AR in the severity of SARS-CoV-2 infection has been hypothesized [32,33,34] and preliminary clinical data indicate that the infusion of either adenosine or of a selective A2AR agonist may dampen inflammation in COVID-19 patients [35,36], our study did not reveal any association between SARS-CoV-2 infection and the rs2298383 SNP of A2AR, a loss-of-function polymorphism associated with bolstered immune response [28]. The gene discussed is ADORA2A; the disease is COVID-19.